Imunon, Inc. · NASDAQ:IMNN

Imunon — Viruses and Cells - Gordon Research Conference 2023

14 slides from Imunon's conference presentation, May 2023

  1. Slide 1: A Novel DNA Vaccine Approach for Prophylactic & Therapeutic Vaccines

    A Novel DNA Vaccine Approach for Prophylactic & Therapeutic Vaccines Khursheed Anwer, PhD., MBA Viruses and Cells - Gordon Research Conference May 21-26, Barcelona, Spain © 2023 IMUNON, Inc. PAGE 1

  2. Slide 2: PlaCCine - Next Generation Covid Vaccine Technology

    PlaCCine- Next Generation Covid Vaccine Technology Well-Suited to Address the Needs of Future Vaccines Known Limitations of Current Covid Vaccines • Short-lived responses (4-6 months) requiring frequent boosts • Low cross-reactivity to new variants • Poor stability at workable temperatures • Poor cy

  3. Slide 3: PlaCCine – A Novel DNA Vaccine Platform: Key Attributes

    PlaCCine – A Novel DNA Vaccine Platform Key Attributes Multiple antigens from a single plasmid Multi-valent Breadth of Immune Responses Durable Responses Durable antigen expression/exposure Novel Formulation Independent of virus, device, or LNPs Flexible Manufacturing “Plug & Play” Stable at >4⁰C >

  4. Slide 4: PlaCCine Technology Platform

    PlaCCine Technology Platform Multicistronic or Single Antigen Vector Formulations Independent of Virus or Device PlaCCine pDNA Constructs PlaCCine Delivery Systems -Synthetic Delivery Systems • Non-viral • Non-device Expression Vector Nanoparticles/Complexes Antigen DNA 1 Antigen DNA 2 Optional Immu

  5. Slide 5: Evidence of Immunogenicity of Prototype PlaCCine Vaccines in Mice

    Evidence of Immunogenicity of Prototype PlaCCine Vaccines in Mice Monovalent & Bivalent Spike Vaccines against Different SARS-CoV-2 Variants IgG nAB Delta LV D614G (Euro) LV ns 4 4 ns 3 3 Log IC50 Titer Log IC50 Titer 2 2 1 1 0 0 Placebo pVac-15 pVac-16 pVac-17 pVac-15 pVac15(125) pVac-16 pVac16(125

  6. Slide 6: Protection Against Viral Challenge in PlaCCine-Vaccinated hACE2:K16 Mice

    Protection Against Viral Challenge in PlaCCine-Vaccinated hACE2:K16 Mice A Bivalent Vaccine Effective Against Multiple Spike Antigen Variants • Formulation: PlaCCine including an adjuvant • Dose - 125 mg DNA 7 days post challenge 10 7 10 6 D614G Challenge- 2.5 X 106 Delta Challenge - 7 X 104 10 6 >

  7. Slide 7: Robust IgG and Neutralizing Antibody Responses to PlaCCine Vaccines in NHP

    Robust IgG and Neutralizing Antibody Responses to PlaCCine Vaccines in NHP Monovalent Vaccines against Different Spike Antigen Variants Day 0 Day 0 NHP Plaque Reduction Neutralization Assay 4wkp2 4wkp2 10 6 10 5 7wkp2 7wkp2 3wkp3 3wkp3 4wkp2 3wkp3 10 5 10 4 7d post-challenge Endpoint Titer 10 4 Tite

  8. Slide 8: Complete Protection Against Viral Challenge is Comparable to mRNA Vaccine

    4 4 Log copie Log copie 4 4 Log copies/m Log copies/m Log copies/ml Log copies Log copies Log copies/ml Log copies/ copies/m Logcopies/ml Log copies/ml Log copies/ 4 4 Log copies/ Log copies/ 4 44 4 4 4 4 4 4 4 3 33 Complete Protection Against Viral Challenge is Comparable to mRNA Vaccine 3 3 3 3 3

  9. Slide 9: Persistent nAB Titers for >14 months after a PlaCCine Covid Vaccine in Mice

    Persistent nAB Titers for >14 months after a PlaCCine Covid Vaccine in Mice Key Feature Required in a Next Generation Vaccine 4 3wkp2 3 8wkp2 12wkp2 Log IC50 Titer 20wkp2 26wkp2 35wkp2 2 1 0 pVac-15 pVac15 pVac-16 pVac16 pVac-17 pVac17 mRNA2P mRNA D614G Delta D614G- Delta D614G © 2023 IMUNON, Inc. P

  10. Slide 10: Cytotoxic T-cell Response Detectable for >14-months in Mice

    Cytotoxic T-cell Response Detectable for >14-months in Mice Potentially Durable Protection from Infection, Mice were immunized at days 0 and 14. Mice were sacrificed at week 60 to assess cellular immune responses. T-cell Response Peptide pools were 15 mers overlapping by 11 aa that encompassed the S

  11. Slide 11: Potent Cross-reactivity with Emerging Variant Following PlaCCine Vaccination

    Potent Cross-reactivity with Emerging Variant Following PlaCCine Vaccination Key Feature Required in a Next Generation Covid Vaccine Day 35 Day 35 IgG Titer (Day 35) neutralization nAb (Day 35) neutralization 10 6 against D614G variant Delta LVagainst Delta variant Delta LV ter IgG Titer 4 4 er prim

  12. Slide 12: Durable IgG & T-cell Responses after a Single Injection

    Durable IgG & T-cell Responses after a Single Injection Favorable comparison to an approved mRNA Vaccine 10 5 IgG Response 2wkp1 500 T-cell Response 4wkp1 (IFN-g) 5wkp1 400 10 4 SFC/106 cells Endpoint Titer 300 10 3 200 100 10 2 0 PBS mRNA pVac50 PBS mRNA pVac50 Peptide pools were 15 mers overlappin

  13. Slide 13: > 9-month Shelf-life at 4⁰C; One-month at Room Temperature

    > 9-month Shelf-life at 4⁰C; One-month at Room Temperature Addressing Key Limitation of mRNA Vaccine Especially in Developing Countries • Vector: pVac-17 (D614G-Delta) • Formulation: PlaCCine IgG Response 10 5 10 4 PLACCINE Endpoint Titer 10 3 4⁰C Storage 1 3 6 9 12 10 2 Months Immunogenicity Studie

  14. Slide 14: PlaCCine: Next Generation Covid Vaccine Technology

    PlaCCine: Next Generation Covid Vaccine Technology Well-Suited to Address the Needs of Future Vaccines • Rapid design & development of vaccines to new variants or targets (3-months from receipt of new antigen sequence(s)) • DNA-based vaccines independent of virus, device or LNPs • Robust humoral and

Imunon — Viruses and Cells - Gordon Research Conference 2023 on 6ix